Bifogade filer
COMMUNIQUÉ FROM EXTRAORDINARY GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL) HELD ON 22 OCTOBER 2024
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Prostatype Genomics AB (publ) reg.no 556726-0285 (the “Company”), listed on the Nasdaq First North Growth Market, held an extraordinary general meeting today on 22 October 2024, whereby the following resolutions were made.
The board’s proposal on amending the articles of association.
The general meeting resolved to amend the articles of association in accordance with the following:
| Current wording | Proposed wording |
| 4. Share capital The share capital shall be not less than SEK 50,000,000 and not more than SEK 200,000,000. | 4. Share capital The share capital shall be not less than SEK 500,000 and not more than SEK 2,000,000. |
| Current wording | Proposed wording |
| 5. Number of shares The number of shares shall be no less than 5,000,000,000 and no more than 20,000,000,000. | 5. Number of shares The number of shares shall be no less than 5,000,000 and no more than 20,000,000. |
The board’s proposal on a reverse split of shares
The general meeting resolved on a reverse share split 1000:1, meaning that 1,000 shares will be consolidated into 1 share. After the reverse split of shares, the number of shares in the Company will amount to 5,148,351.
Further information regarding the reverse split will be presented in a separate press release after the decisions has been registered at the Swedish Companies Registration Office.
Please note that all outstanding warrants (for example the TO4 series warrants) will be recalculated in accordance with the terms applicable to the warrants. The Company will inform about the recalculation through a separate press release.
The board’s proposal on reduction of share capital
The general meeting resolved to reduce the Company's share capital by SEK 50,968,679.06 for allocation to non-restricted equity. This means that the share capital will be reduced from the current SEK 51,483,514.16 to SEK 514,835.10. As a result, the quota value of the Company's share will increase from the current SEK 0.01/share to SEK 0.10/share. The reduction shall be implemented without withdrawal of shares.
The reduction of share capital requires authorization from the Swedish Companies Registration Office.
For further information about Prostatype Genomics, please contact:
Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01
e-mail: fredrik.rickman@prostatypegenomics.com
Certified Advisor
Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, certifiedadviser@carnegie.se
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.